Morgan Drucker, Darren Lee, M. B. Bowman, Xuan Zhang, Bailee Kain, Deedra Nicolet, Roopsha Bandopadhyay, Varsha Singh, Zhe Wang, Richard M. Stone, Caner Saygin, Krzysztof Mrózek, Andrew J. Carroll, Daniel T Starczynowski, Ross L Levine, John C Byrd, Nathan Salomonis, Sarah Skuli, H. Leighton Grimes, Ann-Kathrin Eisfeld, Robert L. Bowman, Linde A. Miles
ABSTRACT: Acute myeloid leukemia (AML) is a multiclonal disease, existing as a milieu of clones with unique but related genotypes as initiating clones acquire subsequent mutations. However, bulk sequencing cannot fully capture AML clonal architecture or the clonal evolution that occurs as patients undergo therapy. To interrogate clonal evolution, we performed simultaneous single-cell molecular profiling and immunophenotyping on 43 samples from 32 patients with NPM1 (nucleophosmin 1)-mutated AML at different time points in disease progression. Here, we show that diagnosis and relapse AML samples display similar clonal architecture patterns, but signaling mutations drive increased clonal complexity, specifically at relapse, which correlates with overall survival. We uncovered unique genotype-immunophenotype relationships regardless of disease state, suggesting leukemic lineage trajectories can be hard-wired by the mutations present. Analysis of longitudinal samples from patients on front-line AML therapy identified dynamic clonal and immunophenotypic changes consistent with the genotype-immunophenotype relationships we identified.